T. Zheng

机构：Harbin Medical University, Third Affiliated Hospital of Harbin Medical University

发表论文 3 篇 · 总被引 2 次 · h-index 1

代表论文

• 1166P A phase I study of JS207, a PD-1/VEGF bispecific antibody, in patients with advanced malignancies (2025 · Annals of Oncology · 被引 2)
• A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma. (2026 · Journal of Clinical Oncology)
• 603O DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced cervical cancer or platinum-resistant recurrent ovarian cancer (2025 · Annals of Oncology)